ReviewCurrent neurology and neuroscience reports2018
Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging.
Review in Current neurology and neuroscience reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- The diagnostic value of SNpc using NM-MRI in Parkinson's disease: meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Pooled it
- One-Year Substantia NigraMovement disorders : official journal of the Movement Disorder Society · 2026Article
- Divergent Glymphatic Dysfunction and Free Water Pathology Underpin Distinct Mechanisms and Enable Differential Diagnosis in Parkinson's Disease and Multiple System Atrophy.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Long-Term Effectiveness and Safety of LCIG in Romania. 3-year Results from a Prospective, Observational Study (DUOGLOBE).Neuropsychiatric disease and treatment · 2026Article
- Synthetic MRI study of brain volume and subcortical myelin in various Parkinson's disease motor subtypes.NPJ Parkinson's disease · 2025Article
- Domain-Specific Prediction of Clinical Progression in Parkinson's Disease Using the Mosaic Approach.Brain and behavior · 2025Article
- Personalized progression modelling and prediction in Parkinson's disease with a novel multi-modal graph approach.NPJ Parkinson's disease · 2024Article
- Increased mean diffusivity of the caudal motor SNc identifies patients with REM sleep behaviour disorder and Parkinson's disease.NPJ Parkinson's disease · 2024Article
- Prediction of cognitive decline in Parkinson's disease based on MRI radiomics and clinical features: A multicenter study.CNS neuroscience & therapeutics · 2024Article
- Exploiting macro- and micro-structural brain changes for improved Parkinson's disease classification from MRI data.NPJ Parkinson's disease · 2024Article
- Article
- Sex differences in human brain networks in normal and psychiatric populations from the perspective of small-world properties.Frontiers in psychiatry · 2024Review
- PET, SPECT, and MRI imaging for evaluation of Parkinson's disease.American journal of nuclear medicine and molecular imaging · 2024Review
- Magnetic Resonance Imaging and Nuclear Imaging of Parkinsonian Disorders: Where do we go from here?Current neuropharmacology · 2024Review
- Volumetric changes and clinical trajectories in Parkinson's disease: a prospective multicentric study.Journal of neurology · 2023Article
- Free-water imaging of the cholinergic basal forebrain and pedunculopontine nucleus in Parkinson's disease.Brain : a journal of neurology · 2023Article
- Serial deep gray nuclear DTI changes in Parkinson's disease over twelve years.Frontiers in aging neuroscience · 2023Article
- Altered Prefrontal Blood Flow Related With Mild Cognitive Impairment in Parkinson's Disease: A Longitudinal Study.Frontiers in aging neuroscience · 2022Article
- Progression of grey and white matter brain damage in Parkinson's disease: a critical review of structural MRI literature.Journal of neurology · 2021Review
- Clinical, Imaging, and Laboratory Markers of Premanifest Spinocerebellar Ataxia 1, 2, 3, and 6: A Systematic Review.Journal of clinical neurology (Seoul, Korea) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewAdvances in neuroimaging techniques pave a rich avenue for in vivo progression biomarkers, which can objectively and noninvasively assess the long-term dynamic alterations in the brain of Parkinson's disease (PD) patients. This article reviews recent progress in structural magnetic resonance imaging (MRI) tools to track disease progression in PD, and discusses specific criteria a neuroimaging tool needs to meet to be a progression biomarker of PD and the potential applications of these techniques in PD based on current evidence. RECENT
findingsRecent longitudinal studies showed that quantitative structural MRI markers derived from T1-weighted, diffusion-weighted, neuromelanin-sensitive, and iron-sensitive imaging have the potential to track disease progression in PD. However, validation of these progression biomarkers is only beginning, and more work is required for multisite validation, the sample size for use in a clinical trial, and drug-responsiveness of most of these biomarkers. At present, the most clinical trial-ready biomarker is free-water diffusion imaging of the substantia nigra and seems well established to be used in disease-modifying studies in PD. A variety of structural imaging biomarkers are promising candidates to be progression biomarkers in PD. Further studies are needed to elucidate the sensitivity, reliability, sample size, and effect of confounding factors of these progression biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.